<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610038</url>
  </required_header>
  <id_info>
    <org_study_id>P050702</org_study_id>
    <nct_id>NCT00610038</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus</brief_title>
  <acronym>GLIDKIR6-2</acronym>
  <official_title>Sulfonylureas in Neonatal Diabetes Mellitus With Mutations of 2 Type of Subunits Kir6.2 and SUR1 of the Pancreatic Beta-cell ATP-sensitive K+ Channel.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our trial is to try to switch patients with permanent neonatal diabetes mellitus&#xD;
      due to a Kir6.2 or SUR1 activating mutation from subcutaneous insulin to oral glibenclamide&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonatal diabetes mellitus, characterized by hyperglycaemia requiring exogenous insulin&#xD;
      therapy appearing during the first months of life, is a rare condition with an estimated&#xD;
      incidence of 1 in 400000 newborns and is permanent in only one-half of the patients[1].&#xD;
      Several studies have identified heterozygous activating mutations of the coding sequence of&#xD;
      KCNJ11 or ABCC8 in patients having a permanent neonatal diabetes mellitus [5,6,7,8]. These&#xD;
      genes encode for the 2 type of subunits Kir6.2 or SUR1 of the pancreatic β-cell ATP-sensitive&#xD;
      K+ channel (KATP channel) which plays a central role in glucose-stimulating insulin&#xD;
      secretion. These channels are also found on muscle and nervous cells, and this may explain&#xD;
      the neurological features sometimes associated with permanent neonatal diabetes mellitus.&#xD;
      Some sulfonylureas, as the glibenclamide, stimulate insulin secretion by binding to SUR1&#xD;
      subunit and closing KATP channels by an ATP-independent mechanism. The glibenclamide is used&#xD;
      efficiently in type 2 diabetes but also recently in replacement of subcutaneous injected&#xD;
      insulin in children with a Kir6.2 or SUR1 activating mutation [7,8,11-13].&#xD;
&#xD;
      The aim of our trial is to try to switch patients with permanent neonatal diabetes mellitus&#xD;
      due to a Kir6.2 or SUR1 activating mutation from subcutaneous insulin to oral glibenclamide&#xD;
      therapy. This study will stand at Necker-Enfants Malades Hospital in the Endocrinology and&#xD;
      Diabetology Unit of the Professors Robert and POLAK. It will include 20 patients, most of&#xD;
      them already identified. This study has two purposes: therapeutic by switching the patients&#xD;
      from subcutaneous insulin to oral glibenclamide therapy, and cognitive by a complementary&#xD;
      evaluation and understanding of the mechanisms of insulin secretion and of glibenclamide&#xD;
      efficiency. To do so, we will assess continuously the capillary glycaemia for three&#xD;
      consecutive days and evaluate the insulin secretion under insulin and sulfonylureas.&#xD;
      Furthermore, we will rate the neurological and developmental status of the patients to seek&#xD;
      for a potential improvement under glibenclamide therapy.&#xD;
&#xD;
      If oral glibenclamide therapy for these patients is proved to be successful, the systematic&#xD;
      search for a Kir6.2 or SUR1 activating heterozygous mutation in newborns with permanent&#xD;
      neonatal diabetes mellitus could be recommended in order to start early oral glibenclamide&#xD;
      therapy and thus extend the indications for the sulfonylureas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assess continuously the capillary glycaemia for three consecutive days and evaluate the insulin secretion under insulin and sulfonylureas</measure>
    <time_frame>permanent</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate the neurological and developmental status of the patients to seek for a potential improvement under glibenclamide therapy</measure>
    <time_frame>every year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the kinetics of glibenclamide in children</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glibenclamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glibenclamide</intervention_name>
    <description>Switching the patients from subcutaneous insulin to oral glibenclamide therapy</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Sulfonylureas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  coding sequence of KCNJ11 or ABCC8 in patients having a permanent neonatal diabetes&#xD;
             mellitus&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypersensibility of sulfonylureas&#xD;
&#xD;
          -  severe renal failure (clearance of creatinemia &lt; 30 ml/min)&#xD;
&#xD;
          -  severe hepatic failure (Prothrombin rate &lt; 70 %)&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  imidazol treatments&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  no social security affiliation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Polak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necker Hospital AP-HP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Necker Hospital - Endocrinology Gynecology Pediatric unit</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <last_update_submitted>November 16, 2012</last_update_submitted>
  <last_update_submitted_qc>November 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neonatal</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>mutation</keyword>
  <keyword>KIR6.2</keyword>
  <keyword>SUR1</keyword>
  <keyword>Neonatal diabetes mellitus with KIR6.2 or SUR1 mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

